BGV (BioGeneration Ventures)

BGV (BioGeneration Ventures) is a leading venture capital firm dedicated to fostering early-stage European life sciences companies. With a strong emphasis on biotech, medtech, and diagnostics, BGV leverages extensive industry expertise to identify and support groundbreaking innovations in healthcare. The company is committed to building world-class teams and driving significant financial returns through strategic investments.

Operating with over €100 million in managed funds, BGV focuses on areas where scientific advancements, unmet medical needs, and the potential for substantial proof of concept converge. BGV actively collaborates with founding teams to nurture scientific progress and construct successful companies. The company’s experience guides ventures through clinical trials, facilitating successful drug development and maximizing value for its investors. BGV's primary address is Gooimeer 2-35, Naarden, 1411DC, NL.

BGV's rigorous selection process ensures that only the most promising opportunities with the greatest prospects for exit are pursued. BGV (BioGeneration Ventures) is known for its successful historical investments, including the divestment of Dezima Pharma to Amgen and Acerta Pharma. BGV (BioGeneration Ventures) continues to seek out and support the next generation of life science innovators. We invite the manager of BGV (BioGeneration Ventures) to create a customized and exclusive company showcase and product listing on our platform to further amplify their reach and impact.